PROMILIAD BIOPHARMA, INC.

Address


ALBERTON, MT, 59820-0010

Information

DUNS: 130194082
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Selective MRTF/SRF-Transcription Inhibitors: Novel Anti-fibrotics for IPF

    Amount: $287,766.00

    DESCRIPTION: Antibiotic resistance among common bacterial pathogens is a serious public health problem as it compromises our ability to treat infectious disease. The resistance problem is compounded ...

    SBIRPhase I2013Department of Health and Human Services
  2. Potent Antifolates as New Therapeutics for MRSA

    Amount: $1,517,860.00

    DESCRIPTION (provided by applicant): This Phase II STTR proposal describes a collaborative effort between researchers in the Department of Pharmaceutical Sciences at the University of Connecticut and ...

    STTRPhase II2010Department of Health and Human Services
  3. New antibiotics targeting fatty acid biosynthesis

    Amount: $171,569.00

    DESCRIPTION (provided by applicant): Antibiotic resistant pathogens, such as methicillin-resistant Staphylococcus aureus, are a significant public health problem which is compounded by the slow rate o ...

    SBIRPhase I2009Department of Health and Human Services
  4. The identification of novel negative allosteric modulators of the nicotinic recep

    Amount: $190,807.00

    DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to identify novel negative allosteric modulators of the nicotinic acetylcholine receptor. This project seeks to partner th ...

    STTRPhase I2009Department of Health and Human Services
  5. Isoindolinones as Antimicrobial Agents

    Amount: $225,624.00

    DESCRIPTION (provided by applicant): Antibiotic resistance among common pathogens is a serious public health problem because it compromises our ability to treat many infectious diseases. The problem h ...

    SBIRPhase I2008Department of Health and Human Services
  6. Natural feedstocks for diversity-oriented synthesis

    Amount: $998,280.00

    DESCRIPTION (provided by applicant): This Phase II STTR application is a continuation of a previous Phase I award between the Wright group at Dartmouth College and Promiliad Biopharma. The goal of thi ...

    STTRPhase II2006Department of Health and Human Services
  7. Potent and selective DHFR inhibitors for treating Cryptosporidiosis

    Amount: $279,271.00

    DESCRIPTION (provided by applicant): This STTR application requests funds to support the transfer of specific biophysical and synthetic expertise from the Anderson and Wright Groups at the University ...

    STTRPhase I2006Department of Health and Human Services
  8. Fermentation initiated antibiotic synthesis

    Amount: $137,162.00

    DESCRIPTION (provided by applicant): This Phase I Small Business Technology Transfer study between Promiliad Biopharma Inc. and Ohio University is focused on a clear prototype demonstration of REBACS, ...

    STTRPhase I2005Department of Health and Human Services
  9. Natural feedstocks for diversity oriented synthesis

    Amount: $100,024.00

    DESCRIPTION (provided by applicant): This STTR application requests funds to support the transfer of specific synthetic expertise and methodologies from the Wright Group at Dartmouth College to inves ...

    STTRPhase I2004Department of Health and Human Services
  10. Natural feedstocks for diversity oriented synthesis

    Amount: $100,024.00

    DESCRIPTION (provided by applicant): This STTR application requests funds to support the transfer of specific synthetic expertise and methodologies from the Wright Group at Dartmouth College to inves ...

    SBIRPhase IDepartment of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government